TrialPharmacology research & perspectives2021

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.

Folke Sjöberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.